...
首页> 外文期刊>Platelets >Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events
【24h】

Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events

机译:试纸蛋白尿是氯吡格雷(而非阿司匹林)接受主要心血管不良事件治疗的患者血小板治疗反应性高的独立预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

The effectiveness of aspirin and clopidogrel in patients with chronic kidney disease (CKD) suffering from acute cardiovascular events is unclear. High on treatment platelet reactivity (HTPR) has been associated with worse outcomes. Here, we assessed the association of dipstick proteinuria (DP) and renal function on HTPR and clinical outcomes. Retrospective cohort analysis of 261 consecutive, non-dialysis patients admitted for Major Adverse Cardiovascular Events (MACE) that had VerifyNow P2Y12 and VerifyNow Aspirin assays performed. HTPR was defined as P2Y12 reactivity unit (PRU) > 208 for clopidogrel and aspirin reaction units (ARU) > 550 for aspirin. Renal function was classified based on the estimated glomerular filtration rate (eGFR), and dipstick proteinuria was defined as >= 30 mg/dl of albumin detected on a spot analysis. All cause mortality, readmissions, and cardiac catheterizations were reviewed over 520 days. In patients on clopidogrel (n = 106), DP was associated with HTPR, independent of eGFR, diabetes mellitus, smoking or use of proton pump inhibitor (AOR = 4.76, p = 0.03). In patients with acute coronary syndromes, HTPR was associated with more cardiac catheterizations (p = 0.009) and readmissions (p = 0.032), but no differences in in-stent thrombosis or re-stenosis were noted in this cohort. In patients on aspirin (n = 155), no associations were seen between DP and HTPR. However, all cause mortality was significantly higher with HTPR in this group (p = 0.038). In this cohort, DP is an independent predictor of HTPR in patients on clopidogrel, but not aspirin, admitted to the hospital for MACE.
机译:阿司匹林和氯吡格雷在患有急性心血管事件的慢性肾脏疾病(CKD)患者中的有效性尚不清楚。血小板反应性高(HTPR)与预后差有关。在这里,我们评估了试纸尿蛋白(DP)和肾功能对HTPR和临床结局的关联。回顾性队列分析了261例接受重大不良心血管事件(MACE)的连续非透析患者,这些患者均进行了VerifyNow P2Y12和VerifyNow阿司匹林测定。 HTPR被定义为氯吡格雷的P2Y12反应单位(PRU)> 208,阿司匹林的反应单位(ARU)> 550。根据估计的肾小球滤过率(eGFR)对肾功能进行分类,将试纸蛋白尿定义为在斑点分析中检测到的白蛋白> = 30 mg / dl。在520天内复查了所有原因导致的死亡率,再入院率和心脏导管插入术。在接受氯吡格雷治疗的患者(n = 106)中,DP与HTPR相关,与eGFR,糖尿病,吸烟或使用质子泵抑制剂无关(AOR = 4.76,p = 0.03)。在患有急性冠状动脉综合征的患者中,HTPR与更多的心脏导管插入术(p = 0.009)和再次入院(p = 0.032)相关,但在该队列中未发现支架内血栓形成或再狭窄的差异。在接受阿司匹林治疗的患者中(n = 155),DP和HTPR之间没有关联。但是,在该组中,使用HTPR的所有原因死亡率均显着更高(p = 0.038)。在这个队列中,DP是接受氯吡格雷治疗但未接受阿司匹林治疗的接受MACE治疗的患者HTPR的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号